DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript
DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance reduction are material for investors, likely prompting a sell‑off.
Market read
First report of Q3 earnings and revised guidance for a large‑cap medical device company.
What to watch
One‑time $39 M accounting benefit and share repurchases could provide short‑term support.
Background
Dentsply Sirona provided its Q3 2026 earnings call transcript, detailing results, segment performance, and updated full‑year guidance.
Market effects
Dental equipment and consumables sector may see broader concerns over demand slowdown.
U.S. dental market pressure could affect related suppliers and distributors.
Limited to dental/medical device niche; no broad macro impact.
Counterpoint
If the company can sustain cost actions and new product momentum, the stock may be oversold.
Key entities
- companyDentsply Sirona
Dental equipment and consumables manufacturer (ticker DENT).
